Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361244 · ClinicalTrials.gov registry record · Phase 1
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00361244: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00361244 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00361244, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of SU011248 and the highest dose of this drug that can be given safely in combination with the chemotherapy drugs irinotecan and cetuximab. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further. Other studies have demonstrated the possibility that SU011248 may enhance the anti-tumor activity of other chemotherapy drugs such as irinotecan and cetuximab.
Interventions
- DRUG Cetuximab
- DRUG Irinotecan
- DRUG SU011248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00361244
The ClinicalTrials.gov registry entry for NCT00361244 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT00361244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00361244 about?
NCT00361244 is a clinical study titled "SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer". The purpose of this study is to determine the safety of SU011248 and the highest dose of this drug that can be given safely in combination with the chemotherapy drugs irinotecan and cetuximab. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prev...
What is the current status of trial NCT00361244?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-07. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00361244?
The interventions under investigation include: Cetuximab (DRUG), Irinotecan (DRUG), SU011248 (DRUG).
Who is sponsoring clinical trial NCT00361244?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.